- Home
- MHF vs IMRX Comparison
MHF vs IMRX Comparison
Compare MHF & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHF
- IMRX
- Stock Information
- Founded
- MHF 1988
- IMRX 2008
- Country
- MHF United States
- IMRX United States
- Employees
- MHF N/A
- IMRX N/A
- Industry
- MHF Finance/Investors Services
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- MHF Finance
- IMRX Health Care
- Exchange
- MHF Nasdaq
- IMRX Nasdaq
- Market Cap
- MHF 145.5M
- IMRX 145.7M
- IPO Year
- MHF N/A
- IMRX 2021
- Fundamental
- Price
- MHF $6.92
- IMRX $3.21
- Analyst Decision
- MHF
- IMRX Strong Buy
- Analyst Count
- MHF 0
- IMRX 4
- Target Price
- MHF N/A
- IMRX $13.25
- AVG Volume (30 Days)
- MHF 57.2K
- IMRX 378.5K
- Earning Date
- MHF 01-01-0001
- IMRX 08-19-2025
- Dividend Yield
- MHF 4.29%
- IMRX N/A
- EPS Growth
- MHF N/A
- IMRX N/A
- EPS
- MHF N/A
- IMRX N/A
- Revenue
- MHF N/A
- IMRX N/A
- Revenue This Year
- MHF N/A
- IMRX N/A
- Revenue Next Year
- MHF N/A
- IMRX N/A
- P/E Ratio
- MHF N/A
- IMRX N/A
- Revenue Growth
- MHF N/A
- IMRX N/A
- 52 Week Low
- MHF $5.92
- IMRX $1.00
- 52 Week High
- MHF $6.79
- IMRX $4.69
- Technical
- Relative Strength Index (RSI)
- MHF 51.29
- IMRX 40.10
- Support Level
- MHF $6.82
- IMRX $3.04
- Resistance Level
- MHF $6.95
- IMRX $3.62
- Average True Range (ATR)
- MHF 0.10
- IMRX 0.23
- MACD
- MHF 0.02
- IMRX -0.11
- Stochastic Oscillator
- MHF 75.00
- IMRX 12.66
About MHF Western Asset Municipal High Income Fund Inc.
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.